Cargando…

Dose patterns in commercially insured subjects chronically exposed to opioids: a large cohort study in the United States

BACKGROUND: Little data exist on how opioid doses vary with the length of exposure among chronic opioid users. METHODS: To characterize the change in the dosage of opioids over time, a retrospective cohort study using the PharMetrics database for the years 1999 through 2008 was conducted. Individual...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cepeda, Maria Soledad, Etropolski, Mila, Weinstein, Rachel, Fife, Daniel, Boston, Raymond, Matcho, Amy
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905346/ https://www.ncbi.nlm.nih.gov/pubmed/20565876 http://dx.doi.org/10.1186/1472-684X-9-14

Ejemplares similares

Treatment patterns and sequences of pharmacotherapy for patients diagnosed with depression in the United States: 2014 through 2019
por: Kern, David M., et al.
Publicado: (2020)

Comparison of the Risks of Shopping Behavior and Opioid Abuse Between Tapentadol and Oxycodone and Association of Shopping Behavior and Opioid Abuse
por: Cepeda, M. Soledad, et al.
Publicado: (2014)

Channeling in the Use of Nonprescription Paracetamol and Ibuprofen in an Electronic Medical Records Database: Evidence and Implications
por: Weinstein, Rachel B., et al.
Publicado: (2017)

Fidelity Assessment of a Clinical Practice Research Datalink Conversion to the OMOP Common Data Model
por: Matcho, Amy, et al.
Publicado: (2014)

Information on doctor and pharmacy shopping for opioids adds little to the identification of presumptive opioid abuse disorders in health insurance claims data
por: Walker, Alexander M, et al.
Publicado: (2019)

Geographic Variation in the Use of Gabapentinoids and Opioids for Pain in a Commercially Insured Adult Population in the United States
por: Zhao, Danni, et al.
Publicado: (2022)

Quantification of missing prescriptions in commercial claims databases: results of a cohort study
por: Cepeda, Maria Soledad, et al.
Publicado: (2017)

Treatment resistant depression incidence estimates from studies of health insurance databases depend strongly on the details of the operating definition
por: Fife, Daniel, et al.
Publicado: (2018)

Ready Conversion of Patients with Well-Controlled, Moderate to Severe, Chronic Malignant Tumor–related Pain on Other Opioids to Tapentadol Extended Release
por: Imanaka, Keiichiro, et al.
Publicado: (2014)

Inferring pregnancy episodes and outcomes within a network of observational databases
por: Matcho, Amy, et al.
Publicado: (2018)

Association of Criminal Statutes for Opioid Use Disorder With Prevalence and Treatment Among Pregnant Women With Commercial Insurance in the United States
por: Gressler, Laura E., et al.
Publicado: (2019)

Opioid and benzodiazepine dispensing and co-dispensing patterns among commercially insured pregnant women in the United States, 2007–2015
por: Qato, Danya M., et al.
Publicado: (2021)

Clinical and economic burden of prescribing tramadol and other opioids for patients with osteoarthritis in a commercially insured population in the United States
por: Silverman, Stuart, et al.
Publicado: (2022)

Naloxone Prescriptions Among Commercially Insured Individuals at High Risk of Opioid Overdose
por: Follman, Sarah, et al.
Publicado: (2019)

Frequency of Early Refills for Opioids in the United States
por: Kern, David M, et al.
Publicado: (2020)

Corrigendum to “Treatment resistant depression incidence estimates from studies of health insurance databases depend strongly on the details of the operating definition” [Heliyon 4 (7) (July 2018) e00707]
por: Fife, Daniel, et al.
Publicado: (2019)

Incidence of Treatment for Opioid Use Disorder Following Nonfatal Overdose in Commercially Insured Patients
por: Kilaru, Austin S., et al.
Publicado: (2020)

Direct Costs of Opioid Abuse in an Insured Population in the United States
por: White, Alan G., et al.
Publicado: (2005)

Direct Costs of Opioid Abuse in an Insured Population in the United States
por: WHITE, ALAN G., et al.
Publicado: (2020)

Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder
por: Tabatabaeepour, Nadia, et al.
Publicado: (2022)

The effect of subjective life expectancy on the participation in commercial pension insurance of Chinese elderly
por: Zhou, Mei, et al.
Publicado: (2022)

The impact of high-risk and chronic opioid use among commercially insured endometriosis patients on health care resource utilization and costs in the United States
por: Estes, Stephanie J, et al.
Publicado: (2020)

1614. Single-Dose Doxycycline as Lyme Disease Post-Exposure Prophylaxis in a National Commercial Insurance Claims Database―the United States, 2014–2017
por: Marx, Grace E, et al.
Publicado: (2019)

Sporotrichosis Cases in Commercial Insurance Data, United States, 2012–2018
por: Benedict, Kaitlin, et al.
Publicado: (2020)

Postpartum care visits among commercially insured women in the United States
por: Butwick, Alexander J., et al.
Publicado: (2022)

Economic Burden of HIV in a Commercially Insured Population in the United States
por: Chen, Cindy Y., et al.
Publicado: (2023)

Epidemiology of rhegmatogenous retinal detachment in commercially insured myopes in the United States
por: Ludwig, Cassie A., et al.
Publicado: (2023)

Non-overdose acute care hospitalizations for opioid use disorder among commercially-insured adults: a retrospective cohort study
por: Raman, Sudha R., et al.
Publicado: (2023)

Trends in opioid use in commercially insured and Medicare Advantage populations in 2007-16: retrospective cohort study
por: Jeffery, Molly Moore, et al.
Publicado: (2018)

Poster 259: Delayed Care and Clinical Outcomes of Medicaid Patients versus Commercially Insured Patients Treated with Arthroscopic Meniscus Repair
por: Boston, Margaret, et al.
Publicado: (2023)

Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States
por: Goodin, Douglas S., et al.
Publicado: (2014)

Presumed ocular histoplasmosis syndrome in a commercially insured population, United States
por: Benedict, Kaitlin, et al.
Publicado: (2020)

Healthcare Utilization and Cost Burden of Porphyria in Commercially Insured Adults in the United States
por: Elsaid, Mohamed I., et al.
Publicado: (2020)

The Hidden Cost of the Opioid Epidemic in the United States: Drug Screening in Insurance Claims
por: Day-Storms, Jeremy J., et al.
Publicado: (2021)

Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study
por: Savitz, Adam, et al.
Publicado: (2021)

Evaluation of Blood Pressure and Heart Rate in Patients with Hypertension Who Received Tapentadol Extended Release for Chronic Pain: A Post Hoc, Pooled Data Analysis
por: Biondi, David M., et al.
Publicado: (2014)

1428. Lyme Disease Treatment in the United States: Prescribing Patterns from a Nationwide Commercial Insurance Database, 2016-2018
por: Beeson, Amy M, et al.
Publicado: (2020)

Coccidioidomycosis Skin Testing in a Commercially Insured Population, United States, 2014–2017
por: Benedict, Kaitlin, et al.
Publicado: (2020)

Direct and Indirect Costs of Infectious Conjunctivitis in a Commercially Insured Population in the United States
por: Pepose, Jay S, et al.
Publicado: (2020)

Cannabis Use and Fungal Infections in a Commercially Insured Population, United States, 2016
por: Benedict, Kaitlin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_iqoh9g36enalpd3iffvg3o2ndq